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OBJECTIVES The purpose of this study was to evaluate benzodiazepine receptor expression on leukocytes
from patients with symptomatic or silent myocardial ischemia.
BACKGROUND Silent myocardial ischemia is frequently observed in patients with coronary artery disease.
Pain can be effectively controlled by various endogenous mechanisms. Benzodiazepines and
their receptors play key roles in pain, in interactions with peptide opioids, in inflammation
and in the response to stress.
METHODS The study group consisted of 57 patients with reproducible exercise-induced myocardial
ischemia. The presence of a constant behavior in the anginal pain perception during both
exercise-induced ischemia and daily life was the most important inclusion criterion. Venous
blood samples were taken from all patients to evaluate the expression of peripheral
benzodiazepine receptors by flow cytometry. The study cohort was classified into two groups:
24 patients who had anginal pain both at home and during the exercise stress test and 33
patients who were asymptomatic during both daily life and exercise-induced ischemia.
RESULTS Flow cytometry analysis showed increased expression of peripheral benzodiazepine receptors
on all types of leukocytes in the asymptomatic patients. The difference was statistically
significant for lymphocytes (p , 0.005), monocytes (p , 0.001) and granulocytes (p ,
0.001).
CONCLUSIONS These data show that expression of peripheral benzodiazepine receptors was higher in patients
with silent myocardial ischemia than in symptomatic patients. (J Am Coll Cardiol 2000;36:
746–50) © 2000 by the American College of Cardiology
Coronary artery disease (CAD) is a progressive atheroscle-
rotic process (1) that results in a spectrum of clinical
manifestations ranging from asymptomatic and stable an-
gina to the acute coronary syndromes, unstable angina,
acute myocardial infarction (MI) and sudden ischemic death
(2). The absence of anginal pain during transitory episodes
of myocardial ischemia occurring during both daily life (3,4)
and stress tests is frequent (5,6); similarly, acute ischemia
during MI and during angioplasty-induced coronary occlu-
sion may not be associated with anginal pain (7,8). The
mechanisms responsible for silent ischemia are not well
understood, and many theories have been advanced (4). The
presence or absence of angina may be partly explained by
individual differences in the pain threshold (5,6). A gener-
alized hyposensitivity to different painful stimuli and a
higher pain threshold have been reported in patients with
silent ischemia compared with symptomatic patients (4–6).
The endogenous opioid system plays an important role in
pain modulation (7). An increase in beta-endorphin plasma
levels, coinciding with an increase in plasma cortisol, has
been documented during exercise as part of the physiologic
stress response (3,8). Benzodiazepines could antagonize
opioid-induced analgesia by enhancing the action of
gamma-aminobutyric acid (GABA) on GABAa receptors in
the pain modulation circuits (9). Some evidence connects
peripheral benzodiazepine receptors (PBRs) with voltage-
dependent calcium channel antagonists in relaxing smooth
muscle and inhibiting beta-endorphin release in a cultured
pituitary cell line (10). In addition, various investigators
have shown that benzodiazepine treatment improves control
of angina (11) and that PBRs could play a role in the stress
response (12), in the interactions of the opioid system (7)
and in steroid biosynthesis (13). Benzodiazepines have been
shown to interact with opioid antinociception (9). Further-
more, in the last few years, the roles of inflammation and
leukocytes in CAD have been underlined (14,15). In pe-
ripheral ischemic and inflamed tissue (16), an interaction
between immune cell–derived opioids and other receptors
localized on sensory nerve terminals can result in strong,
clinically measurable analgesia (17–19). Given that PBRs
affect opioid-induced antinociception and modulation of
pain in animals, we hypothesized that the expression of
PBRs on leukocytes is different in patients with angina than
in patients without anginal symptoms during myocardial
ischemia. We tested this hypothesis by measuring PBRs
expression using flow cytometry on various sets of leuko-
cytes in these two groups of patients.
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METHODS
Patient selection. Our study group consisted of 57 men,
24 of whom reported anginal pain both at home and during
two exercise stress tests (group P) and 33 of whom were
asymptomatic during both daily life and exercise-induced
ischemia (group A). The inclusion criteria were evidence of
myocardial ischemia during these two exercise stress tests
and reproducibility of the same original pain perception or
lack of during both exercise-induced ischemia and daily life
(patients always symptomatic or patients always asymptom-
atic). The patients studied were male because the reproduc-
ibility of pain perception in women can be confounded by
the effects of neurohormonal changes. Patients with inter-
current inflammatory conditions, as well as patients taking
nonsteroidal anti-inflammatory drugs, steroids, benzodiaz-
epine or antiepileptic agents were excluded from the study.
All tests were performed in pharmacologic washout; calcium
channel blocking agents and nitrates were suspended 48 h
before. No patient was receiving beta-blocker therapy at the
time of the study. Beta-blockers were gradually reduced and
stopped one week before our examination. No patient
received digitalis. Informed, written consent for all tests was
obtained from all subjects. The study was approved by the
Ethical Committee of our hospital.
Exercise stress testing. A multistage bicycle ergometric
stress test (EST) was performed in all patients. The initial
work load was 25 W, and the subsequent stepwise incre-
ments were 25 W every 2 min at a pedalling frequency of
60 rpm. A standard 12-lead electrocardiogram (ECG) and
blood pressure were recorded in basal conditions, with the
patient lying in a supine position for 10 min and then just
before the test, at the end of each stage, at the appearance of
ECG signs of ischemia or anginal pain, at peak exercise and
every 3 min during recovery. Three ECG leads (D3, V5, V6)
were continuously monitored and displayed on an oscillo-
scope throughout the test. During the test, the patients were
continuously asked about the onset of angina or other
symptoms. A positive ECG response was defined as the
occurrence of at least 1 mm ST segment depression, as
compared with the baseline tracing. The ischemic threshold
was defined as the appearance of 1 mm flat or downsloping
ST segment depression 0.08 s after the J point; the angina
threshold was defined as the time of the first report of chest
pain during the test. EST was stopped when moderate to
severe angina, dyspnea, muscle fatigue, ST segment depres-
sion .3 mm or major arrhythmias occurred. The rate–
pressure product (RPP: heart rate 3 systolic blood pressure)
was calculated in basal conditions, at the ischemic threshold
and at peak exercise.
Coronary arteriography. All patients underwent cardiac
ventriculography and Sones selective coronary arteriography
within 7 6 5 days after the exercise stress test. Left
ventriculography was performed before coronary arteriogra-
phy in the 30° right anterior oblique projection; ventricular
volumes and left ventricular ejection fraction were calculated
by the standard area–length method. Significant CAD was
defined as $50% narrowing of the lumen of at least one of
the three main arteries or their major branches.
Flow cytometry analysis. Expression of PBRs was mea-
sured by direct immunofluorescence methods using a fluo-
rescent probe (Bodipy Ro-1986, Molecular Probes, Eugene,
Oregon), a fluorescence derived from desdiethylfluorazepam
with a high affinity and selectivity for benzodiazepine
receptors. Venous blood samples were taken from all pa-
tients at 8 AM, before the first exercise stress test, in
reproducible and standardized conditions. The analysis of
PBRs expression on the plasma membrane of the leukocytes
was performed as described.
A sample of 100 ml of Na2 EDTA preserved blood was
treated with 2 ml of ice-cold erythrocyte-lysing solution
(NH4Cl 0.208 g; Na2EDTA 0.1 mg; KHCO3 0.025 g in
250 ml H2O), resuspended in 100 ml of cold phosphate-
buffered saline (PBS) (NaCl 8 g/liter; KCl 0.2 g/liter;
Na2HPO4, 2.89 g/liter; KH2PO4 0.23 g/liter; BSA 2 g/liter;
NaN3 0.2 g/liter) and incubated for 30 min at 0° to 5°C in the
dark with 10 ml of Bodipy Ro-1986 at 5 3 1025 mol/liter.
After incubation, cells were washed three times and then
resuspended in 500 ml of cold PBS containing NaN3 and
analyzed by flow cytometry (Coulter Epics Profile II).
Gating for lymphocytes, monocytes and granulocytes was
determined by the dot blot generated by the forward angle
scatter versus right angle scatter; 10,000 gated cells per
sample were analyzed, and the fluorescence was recorded as
a mean channel number over the logarithmic range of 1 to
1,024. The PBRs are expressed on the plasma membrane
and on the mitochondrial membrane (20); in our study, we
evaluated the plasma membrane sites of PBRs. The expres-
sion of membrane receptors was reported as sites per cell as
described by Caranyon et al. (21).
Binding specificity assay. To verify the fluorescence spec-
ificity, the agonist fluorazepam (without fluorescein) or the
agonist Ro5-4684 (Sigma, St. Louis, Missouri) or the
antagonist PK-11195 (Sigma) was added to our prelabeled
samples. In short, 100 ml of prelabeled cells was incubated
for 30 min at 37°C with 10 ml of fluorazepam 1024 mol/liter
or Ro5-4684 3 3 1024 mol/liter or PK-11195 3 3
1024 mol/liter. After incubation, cells were washed three
times with cold PBS and then resuspended in 250 ml of cold
PBS containing NaN3. Samples were analyzed by flow
cytometry under the same conditions as samples stained
with Bodipy Ro-1986.
Abbreviations and Acronyms
CAD 5 coronary artery disease
DBI 5 diazepam-binding inhibitor
ECG 5 electrocardiogram or electrocardiographic
EST 5 ergometric stress test
GABA 5 g-aminobutyric acid
MI 5 myocardial infarction
PBRs 5 peripheral benzodiazepine receptors
PBS 5 phosphate-buffered saline
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Statistical analysis. Results are expressed as the mean
value 6 SD. Mann-Whitney U nonparametric analysis was
used to investigate differences between the two groups. The
Stat View program for Apple Computers was used, and p ,
0.05 was considered statistically significant.
RESULTS
Our study group consisted of 57 men (mean age 62.5 6
8.6 years) classified into two groups: 24 patients (with a
history of angina pectoris during daily life (group P: 9
patients with effort angina, 4 patients with angina at rest
and 11 patients with mixed angina) and 33 patients with
silent ischemia documented during the exercise stress test
(group A), including 17 patients who had had nonpainful
ischemic episodes during domiciliary Holter recordings.
The other clinical characteristics of the two groups of
patients are reported in Table 1. There were no statistically
significant differences in age, ECG-documented severity of
angina, hypertension, hyperlipidemia, diabetes or smoking.
All patients in group P reported anginal pain during
exercise; moderate to severe dyspnea was experienced during
EST in group A patients. The entity of ST segment
depression at peak exercise was similar between the two
groups.
Patients with silent ischemia had greater expression of
PBRs on leukocytes than did patients reporting angina
pectoris. The binding specificity of PBRs was evaluated
using a high concentration of the agonist Ro5-4684 (Fig. 1).
On lymphocytes, the PBRs expression in group A was
2.0 6 0.4 3 105 sites/cell, and in group P it was 1.2 6 0.4 3
105 sites/cell (p , 0.005). On monocytes, the PBRs
expression in Group A was 13.4 6 0.9 3 105 sites/cell, and
in group P it was 8.0 6 0.5 3 105 sites/cell (p , 0.001). On
granulocytes, the PBRs expression in group A was 7.22 6
0.8 3 105 sites/cell, and in group P it was 4.25 6 0.9 3
105 sites/cell (p , 0.001) (Fig. 2).
DISCUSSION
Our data show that the expression of PBRs on leukocytes
from patients with documented ischemia is significantly
greater in patients with silent ischemia than in patients with
symptomatic ischemia.
The PBRs are expressed on all human peripheral blood
leukocyte subsets, but mainly on monocytes and granulo-
cytes, whereas natural killer cells and B- and T-lymphocytes
display lower levels of PBRs (20). The PBRs have been
Table 1. Clinical, Angiographic and Ergometric Features of Symptomatic (Group P) and




(n 5 33) p Value
Clinical features
Age (years) 60.7 6 8.6 64.9 6 9.4 NS
Arterial hypertension 4 6 NS
Hyperlipidemia 10 14 NS
Diabetes mellitus 3 4 NS
Smoking 9 12 NS
Coronary angiography
Single-vessel disease 10 7 NS
Multivessel disease 14 26 NS
Ejection fraction 58.1 6 10.2 60.1 6 9.4 NS
LVEDV (ml) 115 6 26 124 6 21 NS
LVEDP (mm Hg) 16.4 6 8.1 14.6 6 3.9 NS
EST
Baseline RPP (beats/min 3 mm
Hg)
9.243 6 2.232 9.623 6 2.056 NS
IT-RPP (beats/min 3 mm Hg) 19.978 6 6.723 20.121 6 5.734 NS
Peak RPP (beats/min 3 mm Hg) 21.043 6 4.585 22.347 6 6.573 NS
Peak ST segment depression (mm) 1.92 6 1.51 2.24 6 1.82 NS
Data are presented as the mean value 6 SD or number of patients.
EST 5 exercise stress test; IT 5 ischemic threshold; LVEDP and LVEDV 5 left ventricular end-diastolic pressure and
volume, respectively; RPP 5 rate–pressure product.
Figure 1. The fluorescence intensity of Bodipy Ro-1986 in a symptomatic
patient and in an asymptomatic patient before and after incubation with a
high concentration of the agonist Ro5-4864 without fluorescein. Specific
staining was expressed as the mean channel fluorescence intensity.
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found to modulate immunocyte functions such as chemo-
taxis (22), respiratory burst (21) and cytokine secretion (23).
Modulation of chemotaxis limits the spread of chemotactic
agents and preserves cells from free radical damage (21).
Various endogenous substances, such as diazepam-
binding inhibitor (DBI), are able to bind to PBRs; these
substances have been found in human blood and urine and
are involved in pain control (7,9,12,13). The interaction
between PBRs and morphine-induced antinociception is
abolished by benzodiazepine antagonists such as flumazenil
(9,13), indicating, again, that PBRs are involved in pain
control. Opioid receptors on peripheral sensory nerves are
upregulated during inflammation. Opioid receptors are
expressed on immune cells and can modulate the behavior
and release of cytokines, inducing local analgesia (7). More-
over, neuroactive substances and related receptors could
inhibit nociception of the compromised heart by directly
influencing and modulating the microenvironment (4,7,19).
The absence of pain in certain patients with myocardial
ischemia could be linked to an increased expression of
PBRs. The possible functional significance of the increased
number of benzodiazepine-binding sites on the plasma
membrane could be related to DBI, which enhances the
production of interleukin-1 and tumor necrosis factor (24);
these cytokines are able to increase the expression of
selectins, which have a key role in inflammation-induced
pain (17). A balanced control of pain with PBRs and
opioids may take place through cytokine release.
It is interesting that in epileptic patients, increased DBI
and decreased PBRs are related to increased excitability and
resistance to specific therapy (25), whereas increased PBRs
expression on all leukocyte subsets is related to a decrease of
DBI, which raises the pain threshold (4,6,12,13). Thus, the
concentrations of DBI, opioids and benzodiazepines are
fundamental in the control of pain responses and threshold
of pain. The PBRs may be a critical element in the
interrelation between brain, behavior, immunity and mod-
ulation of pain circuits.
Study limitations. Our study has some limitations. Only
one determination at a single time point was made, but the
samples were analyzed in duplicate. Different endogenous
substances capable of binding to PBRs have been found in
extracts of various rat organs and in human blood and urine,
and a benzodiazepine receptor–mediated model of pain has
also been advanced. We did not test DBI, benzodiazepines
or endorphins in our patients. In this study, we did not
measure the algogenic stimulus in myocardial ischemia, but
we have studied this in a previous report (5).
Conclusions. Increased or decreased PBRs density may
reflect endogenenous ligand activity or regulatory processes
such as DBI or endogenous benzodiazepines. Modifications
of the concentration of DBI or endogenous benzodiazepines
in silent myocardial ischemia could explain the observed
PBRs upregulation. The higher density of PBRs on leuko-
cytes of patients with asymptomatic ischemia is related to
qualitative differences in central and/or peripheral pain
mechanism regulation. Further studies are needed to explain
whether the origin of these different expressions of PBRs are
genetically determined or secondary to the stressful events
and neurohormonal response.
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